DIN 02248676 — IRESSA 250 MG
IRESSA is a tablet of Gefitinib marketed by ASTRAZENECA CANADA INC. The full Gefitinib monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02248676
- Brand name
- IRESSA
- Active ingredient
- Gefitinib
- Strength
- 250 MG
- Dosage form
- TABLET
- Route
- ORAL
- Manufacturer
- ASTRAZENECA CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Gefitinib products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02468050 | APO-GEFITINIB | 250 MG | TABLET | APOTEX INC | MARKETED |
| 02500663 | JAMP GEFITINIB | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED |
| 02491796 | NAT-GEFITINIB | 250 MG | TABLET | NATCO PHARMA (CANADA) INC | DORMANT |